Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5362121 | 0.89 | LMNA (0.37) | MAPK1LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL5366593 | 0.89 | MAPK1 (0.51) | MAPK1LMNAALDH1A1RAPGEF3MAPT | |
| SCHEMBL5370445 | 0.81 | DYRK1A (0.37) | MAPK1LMNAKMT2AALDH1A1RAPGEF3 | |
| SCHEMBL5370647 | 0.79 | ALDH1A1 (0.42) | MAPK1ALDH1A1POLB | |
| SCHEMBL1031505 | 0.70 | MAPT (0.58) | MAPK1LMNAMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL8781907 | 0.69 | MAPT (0.57) | MAPK1LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL5367144 | 0.68 | ALDH1A1 (0.51) | MAPK1LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL5368085 | 0.67 | MAPK1 (0.60) | MAPK1LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL5368049 | 0.67 | MAPK1 (0.63) | MAPK1LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL5378208 | 0.67 | CXCL8 (0.44) | MAPK1LMNAALDH1A1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294716-B2 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALLERGAN, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| EP-1644352-A1 | PROCESS FOR PREPARING ISOMERICALLY PURE PRODRUGS OF PROTON PUMP INHIBITORS | Allergan, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005016917-A1 | PROCESS FOR PREPARING ISOMERICALLY PURE PRODRUGS OF PROTON PUMP INHIBITORS | ALLERGAN, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | SI, ATP6AP1, HRH2 | MAPK1 1186/4885LMNA 1693/4885MEN1 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.